Skip to content

Study · Randomized controlled trial · n = 201 · 2026

7 results

Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.

Masuzaki H, Nagashima H, Shingaki T, Oura T, Tatsuno I

Diabetes, obesity & metabolism10 May 2026Cited by 1 (Europe PMC)

PMID42108080 (opens in a new tab)PMCIDPMC13341361 (opens in a new tab)DOI10.1111/dom.70850 (opens in a new tab)PepBankPUB-42108080
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialOther

    In Japanese adults with obesity disease, across treatment groups, weight loss was correlated with IWQOL-Lite-CT improvements at Week 72 (r values up to -0.32).

    In plain wordsIn Japanese adults with obesity, more weight loss was linked to larger quality-of-life improvements.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCorrelation between weight loss and IWQOL-Lite-CT improvement
    Study

    n = 201

    Analysis
    Exploratory
    Outcome group
    Quality of life · Whole body
    Studied dose
    10 or 15 mg · 72 weeksAs given in this study (human).

    Measurements

    r
    −0.32
    weight loss vs IWQOL-Lite-CT, maximum

    Source sentences

    Summary
    Across treatment groups, weight loss was correlated with IWQOL-Lite-CT improvements at Week 72 (r values up to -0.32), with several correlations reaching statistical significance.
    2 context sentences
    Summary · context
    Post hoc analyses examined correlations between HR-QoL scores and percentage weight loss.
    Summary · context
    Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle modifications.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, both tirzepatide doses significantly improved the IWQOL-Lite-CT Physical Function composite score at Week 72 versus placebo.

    In plain wordsIn Japanese adults with obesity, both tirzepatide doses improved the physical function quality-of-life score more than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIWQOL-Lite-CT Physical Function composite score at Week 72
    Study

    n = 201

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    both tirzepatide doses significantly improved IWQOL-Lite-CT Physical Function composite, Physical composite, Psychosocial composite and Total scores and the SF-36v2 Physical Functioning domain score at Week 72 versus placebo.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle modifications.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, both tirzepatide doses significantly improved the IWQOL-Lite-CT Physical composite score at Week 72 versus placebo.

    In plain wordsIn Japanese adults with obesity, both tirzepatide doses improved the physical quality-of-life score more than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIWQOL-Lite-CT Physical composite score at Week 72
    Study

    n = 201

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    both tirzepatide doses significantly improved IWQOL-Lite-CT Physical Function composite, Physical composite, Psychosocial composite and Total scores and the SF-36v2 Physical Functioning domain score at Week 72 versus placebo.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle modifications.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, both tirzepatide doses significantly improved the IWQOL-Lite-CT Psychosocial composite score at Week 72 versus placebo.

    In plain wordsIn Japanese adults with obesity, both tirzepatide doses improved the psychosocial quality-of-life score more than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIWQOL-Lite-CT Psychosocial composite score at Week 72
    Study

    n = 201

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    both tirzepatide doses significantly improved IWQOL-Lite-CT Physical Function composite, Physical composite, Psychosocial composite and Total scores and the SF-36v2 Physical Functioning domain score at Week 72 versus placebo.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle modifications.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, both tirzepatide doses significantly improved the IWQOL-Lite-CT Total score at Week 72 versus placebo.

    In plain wordsIn Japanese adults with obesity, both tirzepatide doses improved the total quality-of-life score more than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIWQOL-Lite-CT Total score at Week 72
    Study

    n = 201

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    both tirzepatide doses significantly improved IWQOL-Lite-CT Physical Function composite, Physical composite, Psychosocial composite and Total scores and the SF-36v2 Physical Functioning domain score at Week 72 versus placebo.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle modifications.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, both tirzepatide doses significantly improved the SF-36v2 Physical Functioning domain score at Week 72 versus placebo.

    In plain wordsIn Japanese adults with obesity, both tirzepatide doses improved the SF-36 physical functioning score more than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSF-36v2 Physical Functioning domain score at Week 72
    Study

    n = 201

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    both tirzepatide doses significantly improved IWQOL-Lite-CT Physical Function composite, Physical composite, Psychosocial composite and Total scores and the SF-36v2 Physical Functioning domain score at Week 72 versus placebo.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle modifications.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, the effect of tirzepatide on health-related quality of life showed no major variation by sex, baseline body mass index or age.

    In plain wordsIn Japanese adults with obesity, the quality-of-life benefit of tirzepatide was similar across sex, body mass index and age groups.

    Peptide
    Tirzepatide
    Outcome
    No significant changeTreatment effect on HR-QoL by sex, BMI and age subgroup
    Study

    n = 201

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Subgroup analyses showed no major variations in treatment effect by baseline characteristics.
    2 context sentences
    Summary · context
    Prespecified analyses assessed changes from baseline to Week 72 in HR-QoL using the Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) and 36-Item Short-Form Health Survey Version 2.0 (SF-36v2), and assessed subgroup differences by sex (male, female), baseline body mass…
    Summary · context
    Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle modifications.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04844918

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

Eli Lilly and Companyn = 26710 May 2021 to 24 Jun 2023

Obesity

Trial pageClinicalTrials.govUpdated 16 Jul 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.